Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Akebia Therapeutics, Inc.AKBA · Entity 6105 | SVP, CCO | February 28, 2022 | March 03, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Akebia Therapeutics, Inc.
Report date February 28, 2022 · Filed March 03, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 173,841 |
Ending reported balance
After 2022-03-01 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2022-02-28 · Sale · Disposed 6,479 · Balance 130,546 F1: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 26, 2021. Row 2 · 2022-02-28 · Grant · Acquired 50,000 · Balance 180,546 F2: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. One-third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date. Row 3 · 2022-03-01 · Sale · Disposed 5,748 · Balance 174,798 F3: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2020. Row 4 · 2022-03-01 · Sale · Disposed 957 · Balance 173,841 F4: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the performance-based restricted stock units that were previously reported for the Reporting Person on a Form 4 filed on March 18, 2021. |
| Employee Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.16 · Expires 2032-02-28 | Direct | 200,000 |
Reported balance
After 2022-02-28 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-02-28 · Grant · Acquired 200,000 · Balance 200,000 F5: The options were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 26, 2021.
F2: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. One-third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date.
F3: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2020.
F4: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the performance-based restricted stock units that were previously reported for the Reporting Person on a Form 4 filed on March 18, 2021.
F5: The options were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 01, 2022 Filed Mar 3, 2022 02:10 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 957 | $2.17 | $2,077.36 |
DisclosureSEC source: 0001562180-22-002162 · primarydocument.xml · nonDerivative · entry 4 Faulkingham Dell · CIK 0001776024 · SVP, CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,841 F4 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the performance-based restricted stock units that were previously reported for the Reporting Person on a Form 4 filed on March 18, 2021. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 02:10 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 5,748 | $2.17 | $12,477.18 |
DisclosureSEC source: 0001562180-22-002162 · primarydocument.xml · nonDerivative · entry 3 Faulkingham Dell · CIK 0001776024 · SVP, CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,798 F3 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2020. Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 02:10 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantEmployee Stock Option (Right to buy) · Derivative | 200,000 | $0.00 Strike: $2.16 | $0.00 |
DisclosureSEC source: 0001562180-22-002162 · primarydocument.xml · derivative · entry 5 Faulkingham Dell · CIK 0001776024 · SVP, CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2032-02-28 F5 · derivative.exercise_date: The options were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date. Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 02:10 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-002162 · primarydocument.xml · nonDerivative · entry 2 Faulkingham Dell · CIK 0001776024 · SVP, CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,546 F2 · shares: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. One-third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date. Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 02:10 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 6,479 | $2.15 | $13,960.95 |
DisclosureSEC source: 0001562180-22-002162 · primarydocument.xml · nonDerivative · entry 1 Faulkingham Dell · CIK 0001776024 · SVP, CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,546 F1 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 26, 2021. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 00:35 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 952 | $3.40 | $3,236.80 |
DisclosureSEC source: 0001562180-21-002544 · primarydocument.xml · nonDerivative · entry 1 Faulkingham Dell · CIK 0001776024 · SVP, CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,025 F1 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one third of the performance-based restricted stock units that were previously reported for the Reporting Person on a Form 4 filed on March 18, 2021. Read SEC document |
| March 16, 2021 Filed Mar 18, 2021 23:18 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 9,152 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-002357 · primarydocument.xml · nonDerivative · entry 1 Faulkingham Dell · CIK 0001776024 · CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,977 F1 · shares: As previously disclosed, in February 2020, the Reporting Person was granted performance-based restricted stock unit awards ("PSUs") pursuant to the Issuer's 2014 Incentive Plan, as amended. The PSUs vest in connection with the achievement of specified commercial and regulatory milestones. On February 25, 2021, the Company reported its financial results for the year ended December 31, 2020. Subsequently, in accordance with the terms of the grant, the Issuer's Compensation Committee certified the achievement of a commercial milestone and, as a result, one third of the reported PSUs will vest on each of March 31, 2021, February 28, 2022 and February 28, 2023, subject to the Reporting Person's continued service with the Issuer on each vesting date. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 21:08 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 6,749 | $3.40 | $22,920.28 |
DisclosureSEC source: 0001562180-21-001786 · primarydocument.xml · nonDerivative · entry 2 Faulkingham Dell · CIK 0001776024 · CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,825 F2 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2020. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 21:08 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantEmployee Stock Option (Right to buy) · Derivative | 110,000 | $0.00 Strike: $3.46 | $0.00 |
DisclosureSEC source: 0001562180-21-001786 · primarydocument.xml · derivative · entry 3 Faulkingham Dell · CIK 0001776024 · CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires 2031-02-26 F3 · derivative.exercise_date: The options were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 21:08 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 62,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-001786 · primarydocument.xml · nonDerivative · entry 1 Faulkingham Dell · CIK 0001776024 · CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,574 F1 · shares: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date. Read SEC document |
| June 01, 2020 Filed Jun 2, 2020 20:34 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 6,426 | $11.58 | $74,413.08 |
DisclosureSEC source: 0001562180-20-004068 · primarydocument.xml · nonDerivative · entry 1 Faulkingham Dell · CIK 0001776024 · CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,574 F1 · shares: This sale was made to cover tax withholding obligations in connection with the vesting and settlement of 100% of the reporting person's restricted stock units granted on May 31, 2019. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 00:25 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 94,000 | $0.00 Strike: $8.87 | $0.00 |
DisclosureSEC source: 0001562180-20-001929 · primarydocument.xml · derivative · entry 2 Faulkingham Dell · CIK 0001776024 · CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,000 Underlying: Common Stock · 94,000 shares Expires 2030-02-28 F2 · derivative.exercise_date: The options were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 00:25 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 55,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-20-001929 · primarydocument.xml · nonDerivative · entry 1 Faulkingham Dell · CIK 0001776024 · CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 F1 · shares: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date. Read SEC document |
| May 31, 2019 Filed Jun 3, 2019 20:31 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantEmployee Stock Option (Right to buy) · Derivative | 250,000 | $0.00 Strike: $4.45 | $0.00 |
DisclosureSEC source: 0001562180-19-003224 · primarydocument.xml · derivative · entry 2 Faulkingham Dell · CIK 0001776024 · CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2029-05-31 F2 · derivative.exercise_date: The options were granted by the Issuer as an inducement material to the reporting person's entering into employment with Akebia in accordance with Nasdaq Listing Rule 5635(c)(4). The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter. Read SEC document |
| May 31, 2019 Filed Jun 3, 2019 20:31 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-19-003224 · primarydocument.xml · nonDerivative · entry 1 Faulkingham Dell · CIK 0001776024 · CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 F1 · shares: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. 100% of the restricted stock units will vest on the first anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.